Administering Pluvicto™ - A Patient Shares His Treatment Experience of 177Lu-PSMA-617 - Kendra Harris and Phillip Koo

April 22, 2022

From the Tulane Cancer Center, Kendra Harris Chair of Radiation Oncology demonstrates the process of administering a dose of Pluvicto™ (177Lu-PSMA-617).   Phillip Koo meets with the patient in a brief post-dose administration discussion. Lutetium recently received FDA approval as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC).


Kendra Harris, MD, MSc, Chair, Radiation Oncology, Associate Professor, Tulane Cancer Center, Tulane University School of Medicine

Phillip J. Koo, MD, FACS Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona.

Related Content:

Methods for Preparation and Administration of Pluvicto™ (177Lu-PSMA-617) - Kendra Harris

Preparing Your Patient for a 177Lu-PSMA-617 Dose - Kendra Harris

Pluvicto™ (177Lu-PSMA-617) Indications for Clinical Use in PSMA Positive Metastatic Castration-Resistant Prostate Cancer mCRPC - Oliver Sartor

Read the Full Video Transcript

Kendra Harris: All right, Mr. Coon, please have a seat. There we go. All right. You feeling okay today?

Mr. Khan: Yeah. (affirmative)

Kendra Harris: I'm going to go ahead and pull this back. Your labs from yesterday look great. Anything that you're worried about? Any side effects from your last treatment?

Mr. Khan: Not really. No.

Kendra Harris: Anything you want to talk about?

Mr. Khan: Well, everybody been very helpful.

Kendra Harris: Great.

Mr. Khan: Really. I mean, I've been here about six time. I flew out from Chicago to get this treatment. Before that, I had a chemo. Unfortunately, I lost 25 pounds because of chemo and lost all my hair and the hair's all back and I gained back 25 pounds actually. Everything is going well.

Kendra Harris: Great.

Mr. Khan: And I appreciate everybody's help.

Kendra Harris: I'm going to go ahead and go get your dose and bring it in and then we'll be able to do your dosing.

Mr. Khan: All right. Sounds good. Got it.

Kendra Harris: The last thing that I do is to actually wear this covering over my lead apron. Really trying to take every precaution that if there were a tiny flick of contamination, we could deal with it appropriately. The final thing, which I did not point out in the CT room, was to make sure that you have the radiation red bags ready. I'm going to go ahead, now that the patient is ready and take the dose to the CT scanner room. I've also verified all of the patient's labs that he meets criteria for his sixth and final dose, which he does.

I'm going to go ahead and check your IV.

That's great. That's beautiful working.

Mr. Khan: Working Good.

Kendra Harris: My physicist is going to do a survey. Then we're going to do a timeout. Say your name and date of birth for our timeout.

Mr. Khan: [ Mansur foreign language 00:03:21] Khan, July 15th, 1944.

Kendra Harris: My physicist is going to take a quick survey, then we'll be your dosing, okay?

You got it. I'm going to go ahead. You got the time?

Speaker 3: 10:12.

Kendra Harris: Great.

All done. After I disconnect the syringe and replace the top, I'll place it back in the lead igloo. Then I will go ahead and flush. And the final flush. Can you believe it's over? Six doses, just like that. All done. After I remove the last syringe, clean the hub, this double chuck allows me to pick up everything that was used during the administration, including my gloves.

Mr. Khan: You guys do a great job, really. Thank you, thank you.

Kendra Harris: It's our pleasure. We can dispose of this in the red bag, and then I will be back in 15 minutes after your last set of vitals to take your IV out.

Mr. Khan: Got it.

Kendra Harris: Lovely to see you.

Phillip J. Koo: Mr. Khan, if I could ask you a few questions. How has your experience been with this drug now that you received six doses?

Mr. Khan: Well, it has been really positive as compared to the chemo and other things I have done in the past. These people have been very professional. They have informed me ahead of time, everything. For instance, one of the doses that I just got, it does radiate. I had be careful for not being next to the kids for three days to make sure that I don't transmit anything. That really informed me very well. I feel pretty good. Everything seem to be normal at this point. I just finished all six doses. So I'm looking forward to hopefully even better results.

Phillip J. Koo: That's wonderful. No major side effects that you've experienced?

Mr. Khan: Not really. No, I have not. As I said before, when I was taking chemo, I lost like 25 pounds and I lost all my hair. All that I have gained bad now and I got all my hair back. I'm working full-time every day.

Phillip J. Koo: That's that's wonderful. You mentioned a little bit about radiation safety. Has that been a challenge or do you feel like it's been manageable?

Mr. Khan: It's manageable as long as they inform me ahead of time, what can I do and what I cannot do for next three days? I stay away from kids especially, and not really spend too much time close to other people.

Phillip J. Koo: Wonderful. Well, thank you very much for sharing your experience with us.

Mr. Khan: Sure, Well, thank you.